Literature DB >> 23086945

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket.

Lena Sørensen1, Jacob Andersen, Mette Thomsen, Stinna M R Hansen, Xiaobei Zhao, Albin Sandelin, Kristian Strømgaard, Anders S Kristensen.   

Abstract

The serotonin transporter (SERT) and the norepinephrine transporter (NET) are sodium-dependent neurotransmitter transporters responsible for reuptake of released serotonin and norepinephrine, respectively, into nerve terminals in the brain. A wide range of inhibitors of SERT and NET are used as treatment of depression and anxiety disorders or as psychostimulant drugs of abuse. Despite their clinical importance, the molecular mechanisms by which various types of antidepressant drugs bind and inhibit SERT and NET are still elusive for the majority of the inhibitors, including the molecular basis for SERT/NET selectivity. Mutational analyses have suggested that a central substrate binding site (denoted the S1 pocket) also harbors an inhibitor binding site. In this study, we determine the effect of mutating six key S1 residues in human SERT (hSERT) and NET (hNET) on the potency of 15 prototypical SERT/NET inhibitors belonging to different drug classes. Analysis of the resulting drug sensitivity profiles provides novel information on drug binding modes in hSERT and hNET and identifies specific S1 residues as important molecular determinants for inhibitor potency and hSERT/hNET selectivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086945      PMCID: PMC3527955          DOI: 10.1074/jbc.M112.342212

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Chronic and acute regulation of Na+/Cl- -dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems.

Authors:  N R Zahniser; S Doolen
Journal:  Pharmacol Ther       Date:  2001-10       Impact factor: 12.310

2.  Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence.

Authors:  F C Zhou; J H Tao-Cheng; L Segu; T Patel; Y Wang
Journal:  Brain Res       Date:  1998-09-14       Impact factor: 3.252

3.  A new pharmophoric model for 5-HT reuptake-inhibitors: differentiation of amphetamine analogues.

Authors:  A Rupp; K A Kovar; G Beuerle; C Ruf; G Folkers
Journal:  Pharm Acta Helv       Date:  1994-05

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.

Authors:  Wenfei Wang; Mark S Sonders; Okechukwu T Ukairo; Helen Scott; Megan K Kloetzel; Christopher K Surratt
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

6.  Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I.

Authors:  L Keith Henry; Erika M Adkins; Qiao Han; Randy D Blakely
Journal:  J Biol Chem       Date:  2003-07-17       Impact factor: 5.157

7.  Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants.

Authors:  Anders S Kristensen; Mads B Larsen; Laust B Johnsen; Ove Wiborg
Journal:  Eur J Neurosci       Date:  2004-03       Impact factor: 3.386

8.  Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation.

Authors:  Leyla Celik; Steffen Sinning; Kasper Severinsen; Carsten G Hansen; Maria S Møller; Mikael Bols; Ove Wiborg; Birgit Schiøtt
Journal:  J Am Chem Soc       Date:  2008-03-04       Impact factor: 15.419

9.  Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.

Authors:  S Kitayama; S Shimada; H Xu; L Markham; D M Donovan; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol.

Authors:  E L Barker; M A Perlman; E M Adkins; W J Houlihan; Z B Pristupa; H B Niznik; R D Blakely
Journal:  J Biol Chem       Date:  1998-07-31       Impact factor: 5.157

View more
  33 in total

Review 1.  How LeuT shapes our understanding of the mechanisms of sodium-coupled neurotransmitter transporters.

Authors:  Aravind Penmatsa; Eric Gouaux
Journal:  J Physiol       Date:  2013-07-22       Impact factor: 5.182

2.  Importance of the Extracellular Loop 4 in the Human Serotonin Transporter for Inhibitor Binding and Substrate Translocation.

Authors:  Hafsteinn Rannversson; Pamela Wilson; Kristina Birch Kristensen; Steffen Sinning; Anders Skov Kristensen; Kristian Strømgaard; Jacob Andersen
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

3.  A Novel Bromine-Containing Paroxetine Analogue Provides Mechanistic Clues for Binding Ambiguity at the Central Primary Binding Site of the Serotonin Transporter.

Authors:  Rachel D Slack; Ara M Abramyan; Helen Tang; Sitaram Meena; Bruce A Davis; Alessandro Bonifazi; JoLynn B Giancola; Jeffrey R Deschamps; Sett Naing; Hideaki Yano; Satinder K Singh; Amy Hauck Newman; Lei Shi
Journal:  ACS Chem Neurosci       Date:  2019-08-22       Impact factor: 4.418

4.  Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics.

Authors:  Ara M Abramyan; Rachel D Slack; Sitaram Meena; Bruce A Davis; Amy Hauck Newman; Satinder K Singh; Lei Shi
Journal:  Neuropharmacology       Date:  2018-11-01       Impact factor: 5.250

5.  Neurotransmitter and psychostimulant recognition by the dopamine transporter.

Authors:  Kevin H Wang; Aravind Penmatsa; Eric Gouaux
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

6.  Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

Authors:  Mu-Fa Zou; Jianjing Cao; Ara M Abramyan; Theresa Kopajtic; Claudio Zanettini; Daryl A Guthrie; Rana Rais; Barbara S Slusher; Lei Shi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-12-11       Impact factor: 7.446

7.  X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine.

Authors:  Aravind Penmatsa; Kevin H Wang; Eric Gouaux
Journal:  Nat Struct Mol Biol       Date:  2015-05-11       Impact factor: 15.369

8.  The role of cysteines and histidins of the norepinephrine transporter.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

9.  Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.

Authors:  Ashwini K Banala; Peng Zhang; Per Plenge; George Cyriac; Theresa Kopajtic; Jonathan L Katz; Claus Juul Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2013-12-02       Impact factor: 7.446

10.  X-ray structure of dopamine transporter elucidates antidepressant mechanism.

Authors:  Aravind Penmatsa; Kevin H Wang; Eric Gouaux
Journal:  Nature       Date:  2013-09-15       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.